TVARDI THERAPEUTICS INC (TVRD) Stock Price & Overview
NASDAQ:TVRD • US1407553072
Current stock price
The current stock price of TVRD is 3.64 USD. Today TVRD is down by -6.43%. In the past month the price decreased by -0.27%.
TVRD Key Statistics
- Market Cap
- 34.143M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -8.36
- Dividend Yield
- N/A
TVRD Stock Performance
TVRD Stock Chart
TVRD Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TVRD.
TVRD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TVRD. TVRD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TVRD Earnings
TVRD Forecast & Estimates
14 analysts have analysed TVRD and the average price target is 15.15 USD. This implies a price increase of 316.32% is expected in the next year compared to the current price of 3.64.
For the next year, analysts expect an EPS growth of -91.17% and a revenue growth -93.23% for TVRD
TVRD Groups
Sector & Classification
TVRD Financial Highlights
Over the last trailing twelve months TVRD reported a non-GAAP Earnings per Share(EPS) of -8.36. The EPS increased by 85.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.74% | ||
| ROE | -50.04% | ||
| Debt/Equity | 0 |
TVRD Ownership
TVRD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.61 | 933.096B | ||
| JNJ | JOHNSON & JOHNSON | 20.44 | 586.064B | ||
| MRK | MERCK & CO. INC. | 22.39 | 285.388B | ||
| PFE | PFIZER INC | 9.19 | 151.312B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.43 | 121.598B | ||
| ZTS | ZOETIS INC | 17.19 | 49.875B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.92 | 26.593B | ||
| VTRS | VIATRIS INC | 5.5 | 15.555B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.94 | 11.634B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.093B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.204B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.893B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.85 | 4.144B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TVRD
Company Profile
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company is headquartered in Sugar Land, Texas and currently employs 10 full-time employees. The company went IPO on 2014-01-31. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Company Info
IPO: 2014-01-31
TVARDI THERAPEUTICS INC
3 Sugar Creek Ctr Blvd, Ste 525
Sugar Land TEXAS US
Employees: 10
Phone: 17134898654
TVARDI THERAPEUTICS INC / TVRD FAQ
What does TVRD do?
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company is headquartered in Sugar Land, Texas and currently employs 10 full-time employees. The company went IPO on 2014-01-31. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
What is the stock price of TVARDI THERAPEUTICS INC today?
The current stock price of TVRD is 3.64 USD. The price decreased by -6.43% in the last trading session.
Does TVRD stock pay dividends?
TVRD does not pay a dividend.
How is the ChartMill rating for TVARDI THERAPEUTICS INC?
TVRD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about TVARDI THERAPEUTICS INC (TVRD) stock?
14 analysts have analysed TVRD and the average price target is 15.15 USD. This implies a price increase of 316.32% is expected in the next year compared to the current price of 3.64.
Would investing in TVARDI THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TVRD.
Can you provide the upcoming earnings date for TVARDI THERAPEUTICS INC?
TVARDI THERAPEUTICS INC (TVRD) will report earnings on 2026-05-11.